Dimensional Fund Advisors LP Sells 155,444 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Dimensional Fund Advisors LP decreased its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 47.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 171,185 shares of the company’s stock after selling 155,444 shares during the quarter. Dimensional Fund Advisors LP owned 0.20% of Dyne Therapeutics worth $6,041,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in DYN. Nisa Investment Advisors LLC boosted its holdings in shares of Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after acquiring an additional 669 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of Dyne Therapeutics by 28.0% during the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after purchasing an additional 1,291 shares in the last quarter. EntryPoint Capital LLC acquired a new position in shares of Dyne Therapeutics in the first quarter valued at approximately $214,000. SG Americas Securities LLC bought a new position in Dyne Therapeutics in the 2nd quarter valued at approximately $217,000. Finally, American Century Companies Inc. acquired a new stake in Dyne Therapeutics during the 2nd quarter worth approximately $228,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Dyne Therapeutics

In other news, CEO John Cox acquired 32,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was bought at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the acquisition, the chief executive officer now owns 8,000 shares in the company, valued at $264,320. The trade was a -100.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Dyne Therapeutics news, CEO John Cox acquired 32,000 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 4th. The stock was acquired at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the purchase, the chief executive officer now owns 8,000 shares of the company’s stock, valued at approximately $264,320. This represents a -100.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Susanna Gatti High sold 8,976 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total value of $308,864.16. Following the sale, the chief operating officer now owns 131,636 shares in the company, valued at approximately $4,529,594.76. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 135,304 shares of company stock valued at $4,857,019. Company insiders own 20.77% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of DYN stock opened at $33.13 on Wednesday. The firm has a 50-day moving average of $38.92 and a 200-day moving average of $34.24. Dyne Therapeutics, Inc. has a one year low of $6.40 and a one year high of $47.45. The company has a market cap of $2.89 billion, a P/E ratio of -8.35 and a beta of 1.05.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. As a group, research analysts expect that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on DYN. Stifel Nicolaus upped their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, August 16th. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, September 4th. Oppenheimer restated an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Piper Sandler reiterated an “overweight” rating and set a $53.00 price objective on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Finally, StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.